Appendix 1 Supplemental Methods

Therapeutic regimens

Chemotherapy and chemoradiotherapy regimens in lung cancer

The chemotherapy in patients with limited stage-small cell lung cancer (LS-SCLC) consisted of etoposide and cisplatin/carboplatin, and was administered intravenously for a maximum of 6–8 cycles. Patients in chemoradiotherapy group were planned to 45 Gy in 3 weeks or 60–70 Gy in 6–7 weeks.

Non-small cell lung cancer (NSCLC) patients on stage IB with high risk factors underwent postoperative adjuvant chemotherapy, mainly using nivolumab and platinum. Patients with NSCLC on stage II were treated with platinum-containing adjuvant chemotherapy after surgery. For resectable NSCLC on stage III, adjuvant platinum-containing chemotherapy is followed after complete resection; For unresectable NSCLC on stage III, platinum-based concurrent chemotherapy regimen includes: (I) PC: paclitaxel and carboplatin; (II) DP: docetaxel and cisplatin; (III) AP/AC: pemetrexed and cisplatin/carboplatin; (IV) EP: etoposide and cisplatin. The radical prescription dose in chemoradiotherapy group was 60–70 Gy, 2 Gy every time. Radiotherapy target includes primary lesion and metastatic lymph node involvement. The mean heart dose constraint was below 10 Gy. All routine planned CT scans of radiotherapy were performed on a Phillips Brilliance Big Bore 16 slice CT scanner (Philips Healthcare, Amsterdam, The Netherlands) with the same parameters (non-contrast and using 3 mm slices).

Chemotherapy and chemoradiotherapy regimens in esophageal cancer

Chemotherapy regimens commonly consisted of fluoropyrimidine, combined with platinum- or taxane-based compound, and was administered intravenously for a maximum of 6–8 cycles. In chemoradiotherapy group, preoperative neoadjuvant radiotherapy or concurrent chemoradiotherapy: 95% Planning Target Volume (PTV) 40–50 Gy/1.8–2.0 Gy for 5 times a week. The postoperative radical radiotherapy or concurrent chemoradiotherapy: (I) 95% PTV 60 Gy/1.8–2.0 Gy for 5 times a week. (II) 95% PTV 50 Gy/1.8–2.0 Gy, sequential 95% PTV 10 Gy/1.8–2.0 Gy for 5 times a week. The mean heart dose constraint was below 15 Gy. All routine planned CT scans of radiotherapy were performed on a Phillips Brilliance Big Bore 16 slice CT scanner (Philips Healthcare, Amsterdam, The Netherlands) with the same parameters (non-contrast and using 3 mm slices). The esophageal cancer patients were immobilized in the supine position, with their arms straight on the side or their hands crossed on the forehead. Patients with cervical and upper segments were recommended to fix the head, neck and shoulder mask, and the body membrane of the middle and lower segment and esophageal-gastric junction cancer is fixed. Ven-enhanced scan was performed with the thickness of 0.5 cm. People with a history of contrast allergy cannot perform enhanced scans.

Chemotherapy and chemoradiotherapy regimens in breast cancer

The concurrent chemotherapy consisted of epirubicin (area under the curve: 2 mg/mL per min) and pirarubicin (50 mg/m^2 of body-surface area), and was administered intravenously for a maximum of 6–8 cycles. Patients in chemoradiotherapy group were planned to 60 Gy in 30 fractions or 50 Gy in 25 fractions with intensity modulated proton therapy according to radiation oncologist. The mean heart dose constraint was below 5 Gy. All routine planned CT scans of radiotherapy were performed on a Phillips Brilliance Big Bore 16 slice CT scanner (Philips Healthcare, Amsterdam, The Netherlands) with the same parameters (non-contrast and using 3 mm slices). The breast cancer patients were immobilized in the same supine position with breast position fixed, and both arms above the head. The radiotherapy schemes in this group were all using tangential left breast radiotherapy with deep inspiration breath-hold.

https://dx.doi.org/10.21037/qims-24-944

Table S1 CAD-RADS classification

Category	Degree of maximal coronary stenosis	Interpretation
CAD-RADS 0	0% (No plaque or stenosis)	Absence of CAD
CAD-RADS 1	1–24% (Minimal stenosis or plaque with no stenosis)	Minimal non-obstructive CAD
CAD-RADS 2	25–49% (Mild stenosis)	Mild non-obstructive CAD
CAD-RADS 3	50–69% (Moderate stenosis)	Moderate stenosis
CAD-RADS 4	A: 70–99% stenosis; or B: left main >50% or 3-vessel obstructive (>70%) disease	Severe stenosis
CAD-RADS 5	100% (total occlusion)	Total coronary occlusion or sub-total occlusion

CAD-RADS, coronary artery disease-reporting and data system; CAD, coronary artery disease.

Table S2 Clinical characteristics of each cancer

Parameters	Chemotherapy			Chemoradiotherapy		
	Pretreatment	Posttreatment	P*	Pretreatment	Posttreatment	P**
Lung cancer (n=855)						
Age (years)	70.00 (64.00, 75.00)	70.00 (68.00, 72.00)	0.455	68.00 (61.00, 72.00)	68.00 (58.00, 74.00)	0.827
Sex			0.085			0.850
Female	126 (45.0)	112 (52.8)		109 (48.9)	67 (47.9)	
Male	154 (55.0)	100 (47.2)		114 (51.1)	73 (52.1)	
Body mass index (kg/m^2)	23.55±3.38	23.25±3.35	0.972	23.57±3.47	23.20±3.35	0.650
Obesity	21 (7.5)	15 (7.1)	0.858	15 (6.7)	10 (7.1)	0.879
Hypertension	93 (33.2)	66 (31.1)	0.625	74 (33.2)	49 (35.0)	0.722
Diabetes mellitus	28 (10.0)	30 (14.2)	0.157	34 (15.2)	15 (10.7)	0.219
Smoking	246 (87.9)	176 (83.0)	0.128	186 (83.4)	116 (82.9)	0.891
Dyslipidemia	198 (70.7)	138 (65.1)	0.185	146 (65.5)	93 (66.4)	0.851
Previous MI	6 (2.1)	8 (3.8)	0.421	9 (4.0)	6 (4.3)	0.877
Known CAD	121 (43.2)	93 (43.9)	0.957	93 (41.7)	59 (42.1)	0.978
Previous HF	6 (2.1)	8 (3.8)	0.421	11 (4.9)	7 (5.0)	0.826
TNM			0.973			0.569
I	35 (12.5)	28 (13.2)		19 (8.5)	9 (6.4)	
II	83 (29.6)	62 (29.2)		56 (25.1)	31 (22.1)	
III	162 (57.9)	122 (57.5)		148 (66.4)	100 (71.4)	
IV	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Medication use						
Beta-blocker	18 (6.4)	17 (8.0)	0.615	15 (6.7)	10 (7.1)	0.951
Ca2+ channel blocker	20 (7.1)	17 (8.0)	0.715	16 (7.2)	8 (5.7)	0.586
ACEI/ARB	55 (7.9)	19 (9.0)	0.661	21 (9.4)	10 (7.1)	0.450
Statin	53 (18.9)	38 (17.9)	0.776	44 (19.7)	25 (17.9)	0.658
Aspirin	23 (8.2)	15 (7.1)	0.639	17 (7.9)	9 (6.4)	0.667
Mean heart dose	–	–		–	5.99±7.76Gy	
Esophageal cancer (n=376)						
Age (years)	66.00 (59.00, 73.00)	67.00 (64.00, 72.00)	0.449	69.00 (56.50, 74.00)	69.00 (60.75, 73.25)	0.354
Sex			0.808			0.287
Female	42 (56.0)	36 (58.1)		59 (43.1)	51 (50.0)	
Male	33 (44.0)	26 (41.9)		78 (56.9)	51 (50.0)	
Body mass index (kg/m^2)	23.35±3.19	22.54±3.40	0.699	23.47±3.31	22.24±7.21	0.079
Obesity	4 (5.3)	2 (3.2)	0.549	9 (6.6)	6 (5.9)	0.829
Hypertension	26 (34.7)	16 (25.8)	0.263	52 (38.0)	28 (27.5)	0.089
Diabetes mellitus	8 (10.7)	4 (6.5)	0.385	19 (13.9)	18 (17.6)	0.424
Smoking	65 (86.7)	54 (87.1)	0.941	120 (87.6)	83 (81.4)	0.184
Dyslipidemia	49 (65.3)	46 (74.2)	0.263	87 (63.5)	85 (83.3)	0.001
Previous MI	4 (5.3)	5 (8.1)	0.731	4 (2.9)	3 (2.9)	0.922
Known CAD	31 (41.3)	24 (38.7)	0.891	55 (40.1)	41 (40.2)	0.994
Previous HF	3 (4.0)	3 (4.8)	0.811	4 (2.9)	3 (2.9)	0.922

Table S2 *(continued)*

https://dx.doi.org/10.21037/qims-24-944

Table S2 *(continued)*

Parameters	Chemotherapy			Chemoradiotherapy		
	Pretreatment	Posttreatment	P*	Pretreatment	Posttreatment	P**
TNM			0.939			<0.001
I	9 (12.0)	6 (9.7)		19 (13.9)	9 (8.8)	
II	20 (26.7)	15 (24.2)		51 (37.2)	16 (15.7)	
III	26 (34.7)	24 (38.7)		50 (36.5)	53 (52.0)	
IVA	20 (26.7)	17 (27.4)		17 (12.4)	24 (23.5)	
Medication use						
Beta-blocker	5 (6.7)	5 (8.1)	0.754	10 (7.3)	8 (7.8)	0.875
Ca2+ channel blocker	7 (9.3)	4 (6.5)	0.537	10 (7.3)	7 (6.9)	0.897
ACEI/ARB	5 (6.7)	3 (4.8)	0.650	9 (6.6)	8 (7.8)	0.705
Statin	14 (18.7)	12 (19.3)	0.919	28 (20.4)	20 (19.6)	0.874
Aspirin	5 (6.7)	5 (8.1)	0.754	11 (8.0)	9 (8.8)	0.826
Mean heart dose (Gy)	–	–		–	8.25±10.02Gy	
Breast cancer (n=312)						
Age (years)	52.50 (46.00, 62.25)	54.00 (47.00, 62.00)	0.948	49.00 (46.00, 56.00)	49.00 (46.50, 56.00)	0.802
Sex			0.745			NA
Female	85 (94.4)	85 (95.5)		68 (100.0)	65 (100.0)	
Male	5 (5.6)	4 (4.5)		0 (0.0)	0 (0.0)	
Body mass index (kg/m^2)	23.05±3.30	22.60±3.38	0.369	22.86±3.59	22.16±3.42	0.252
Obesity	6 (6.7)	4 (4.5)	0.527	7 (10.3)	5 (7.8)	0.620
Hypertension	33 (18.4)	26 (19.5)	0.804	14 (20.6)	12 (18.5)	0.757
Diabetes mellitus	14 (15.5)	13 (14.6)	0.165	7 (10.3)	6 (9.2)	0.836
Smoking	27 (30.0)	28 (29.2)	0.700	10 (14.7)	8 (12.3)	0.686
Dyslipidemia	34 (37.7)	30 (33.7)	0.273	11 (16.2)	8 (12.3)	0.524
Previous MI	2 (2.2)	3 (3.4)	0.641	1 (1.5)	3 (4.6)	0.288
Known CAD	36 (40.0)	37 (41.6)	0.830	29 (42.6)	27 (41.5)	0.897
Previous HF	1 (1.1)	3 (3.4)	0.306	0 (0.0)	1 (1.5)	0.305
TNM			0.892			0.994
I	8 (9.0)	10 (11.2)		4 (5.9)	4 (6.2)	
II	40 (44.4)	39 (43.8)		29 (42.6)	29 (44.6)	
III	31 (34.4)	30 (33.7)		28 (41.2)	26 (40.0)	
IV	11 (12.2)	10 (11.2)		7 (10.3)	6 (9.2)	
Medication use						
Beta-blocker	6 (6.7)	7 (7.9)	0.757	5 (7.3)	5 (7.7)	0.798
Ca2+ channel blocker	7 (7.8)	7 (7.9)	0.983	6 (8.8)	4 (6.3)	0.577
ACEI/ARB	4 (4.4)	4 (4.5)	0.987	15 (22.0)	14 (21.5)	0.890
Statin	17 (18.9)	17 (19.1)	0.971	13 (19.1)	11 (16.9)	0.917
Aspirin	5 (5.6)	5 (5.6)	0.985	6 (8.8)	4 (6.3)	0.577
Mean heart dose (Gy)	–	–		–	3.51±1.17	

Values are mean ± standard deviation, median (interquartile range) or n (%). *, P values reflect the differences between pretreatment and posttreatment in the chemotherapy group; **, P values reflect the differences between pretreatment and posttreatment in the chemoradiotherapy group. MI, myocardial infarction; CAD, coronary artery disease; HF, heart failure; TNM, tumor node metastasis; ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker; NA, not available.

https://dx.doi.org/10.21037/qims-24-944

Table S3 Baseline characteristics between patients with MACEs and without MACEs

Characteristic	MACEs (n=232)	Non-MACEs (n=1,311)	P
Age (years)	65.00 (56.00, 72.00)	66.00 (56.00, 72.00)	0.347
Sex			
Female	126 (54.3)	779 (59.4)	0.145
Male	106 (45.7)	532 (40.6)	
Body mass index (kg/m^2)	23.45±3.36	23.37±3.38	
Obesity	18 (7.8)	87 (6.6)	0.531
Hypertension	75 (32.3)	388 (29.6)	0.403
Diabetes mellitus	34 (14.7)	162 (12.4)	0.333
Smoking	158 (68.1)	933 (71.2)	0.345
Dyslipidemia	128 (55.2)	767 (58.5)	0.343
Previous MI	8 (3.4)	46 (3.5)	0.963
Known CAD	90 (38.8)	556 (42.4)	0.303
Previous HF	4 (1.7)	46 (3.5)	0.157
TNM			0.212
I	21 (9.0)	123 (9.4)	
II	58 (25.0)	388 (29.6)	
III	119 (51.3)	662 (50.5)	
IV	34 (14.7)	138 (10.5)	
Medication use			
Beta-blocker	17 (7.3)	94 (7.2)	0.932
Ca2+ channel blocker	15 (6.5)	98 (7.5)	0.586
ACEI/ARB	15 (6.5)	97 (7.4)	0.613
Statin	36 (15.5)	256 (19.5)	0.151
Aspirin	15 (6.5)	99 (7.6)	0.560
CCTA parameters			
Total coronary artery calcium score			0.089
0 (0)	71 (30.6)	422 (32.2)	
1 (1 to 10)	16 (6.9)	144 (11.0)	
2 (11 to 100)	36 (15.5)	232 (17.7)	
3 (101 to 400)	46 (19.8)	244 (18.6)	
4 (>400)	63 (27.2)	269 (20.5)	
Total coronary diameter stenosis			0.656
None (0%)	107 (24.0)	75 (20.7)	
Slight (1% to 24%)	43 (9.7)	33 (9.0)	
Mild (25% to 49%)	84 (18.9)	82 (22.6)	
Moderate (50% to 69%)	107 (24.0)	87 (24.0)	
Severe (70% to 99%)	104 (23.4)	86 (23.7)	
CAD-RADS classification			
0	47 (20.2)	328 (25.0)	0.474
1	18 (7.8)	108 (8.2)	
2	44 (19.0)	250 (19.1)	
3	57 (24.6)	310 (23.7)	
4	66 (28.4)	315 (24.0)	
5	0 (0.0)	0 (0.0)	
LVEF (%)	54.9±5.5	54.2±6.4	0.117
LVEDV (mL)	117.4±14.7	118.6±15.5	0.274
LVESV (mL)	51.6±9.8	53.0±10.4	0.057
LVSV (mL)	65.3±12.1	65.1±13.2	0.830
LVMM (g)	94.6±14.8	96.6±15.9	0.075
FAI of LAD (HU)	−70.2±12.4	−75.1±7.4	<0.001
FAI of LCX (HU)	−70.3±12.7	−75.1±6.7	<0.001
FAI of RCA (HU)	−69.8±12.7	−75.2±6.2	<0.001

Values are mean ± standard deviation, median (interquartile range) or n (%). P values reflect the differences between the patients with MACEs and without MACEs. MACEs, major adverse cardiovascular events; MI, myocardial infarction; CAD, coronary artery disease; HF, heart failure; TNM, tumor node metastasis; ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker; CCTA, coronary computed tomography angiography; CAD-RADS, coronary artery disease-reporting and data system; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVMM, left ventricular myocardial mass; FAI, fat attenuation index; LAD, left anterior descending artery; HU, Hounsfield unit; LCX, left circumflex artery; RCA, right coronary artery.

https://dx.doi.org/10.21037/qims-24-944

Table S4 The comparison of CCTA parameters of three coronary arteries before and after treatment in chemotherapy and chemoradiotherapy

Parameters	Chemotherapy			Chemoradiotherapy		
	Pretreatment (n=445)	Posttreatment (n=363)	P	Pretreatment (n=428)	Posttreatment (n=307)	P
LAD diameter stenosis			0.799			0.839
None (0%)	176 (39.6)	137 (37.7)		165 (38.6)	119 (38.8)	
Slight (1% to 24%)	55 (12.4)	38 (10.5)		42 (9.8)	28 (9.1)	
Mild (25% to 49%)	69 (15.5)	65 (17.9)		69 (16.1)	59 (19.2)	
Moderate (50% to 69%)	85 (19.1)	74 (20.4)		86 (20.1)	57 (18.6)	
Severe (70% to 99%)	60 (13.5)	49 (13.5)		66 (15.4)	44 (14.3)	
LCX diameter stenosis			0.896			0.705
None (0%)	273 (61.3)	217 (59.8)		240 (56.1)	174 (56.7)	
Slight (1% to 24%)	39 (8.8)	34 (9.4)		43 (10.0)	28 (9.1)	
Mild (25% to 49%)	57 (12.8)	53 (14.6)		67 (15.7)	40 (13.0)	
Moderate (50% to 69%)	49 (11.0)	35 (9.6)		47 (11.0)	36 (11.7)	
Severe (70% to 99%)	27 (6.1)	24 (6.6)		31 (7.2)	29 (9.4)	
RCA diameter stenosis			0.503			0.550
None (0%)	243 (54.6)	183 (50.4)		215 (50.2)	168(54.7)	
Slight (1% to 24%)	43 (9.7)	37 (10.2)		45 (10.7)	35 (11.4)	
Mild (25% to 49%)	54 (12.1)	58 (16.0)		59 (13.8)	42 (13.7)	
Moderate (50% to 69%)	59 (13.3)	52 (14.3)		71 (16.6)	38 (12.4)	
Severe (70% to 99%)	46 (10.3)	33 (9.1)		37 (8.6)	24 (7.8)	
LAD coronary artery calcium score			0.275			0.951
0 (0)	208 (46.7)	147 (40.5)		223 (52.1)	157 (51.1)	
1 (1 to 10)	49 (11.0)	56 (15.4)		28 (6.5)	24 (7.8)	
2 (11 to 100)	65 (14.6)	54 (14.9)		68 (15.9)	52 (16.9)	
3 (101 to 400)	71 (16.0)	64 (17.6)		71 (16.6)	48 (15.6)	
4 (>400)	52 (11.7)	42 (11.6)		38 (8.9)	26 (8.5)	
LCX coronary artery calcium score			0.191			0.832
0 (0)	264 (59.3)	228 (62.8)		273 (63.8)	199 (63.8)	
1 (1 to 10)	31 (7.0)	17 (4.7)		39 (9.1)	24 (7.8)	
2 (11 to 100)	54 (12.1)	56 (15.4)		47 (11.0)	40 (13.0)	
3 (101 to 400)	69 (15.5)	42 (11.6)		42 (9.8)	28 (9.1)	
4 (>400)	27 (6.1)	20 (5.5)		27 (6.3)	16 (5.2)	
RCA coronary artery calcium score			0.938			0.803
0 (0)	250 (56.2)	204 (56.2)		251 (58.6)	181 (59.0)	
1 (1 to 10)	40 (9.0)	28 (7.7)		41 (9.6)	28 (9.1)	
2 (11 to 100)	60 (13.5)	55 (15.2)		57 (13.3)	39 (12.7)	
3 (101 to 400)	53 (11.9)	43 (11.8)		40 (9.3)	36 (11.7)	
4 (>400)	42 (9.4)	33 (9.1)		39 (9.1)	23 (7.5)	

CCTA, coronary computed tomography angiography; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.

https://dx.doi.org/10.21037/qims-24-944

Table S5 The comparison of CCTA parameters before and after chemotherapy in thoracic cancer

Parameters	Lung cancer			Esophageal cancer			Breast cancer		
	Pre (n=280)	Post (n=212)	P	Pre (n=75)	Post (n=62)	P	Pre (n=90)	Post (n=89)	P
Total coronary artery calcium score			0.212			0.772			0.661
0 (0)	63 (22.5)	45 (21.2)		18 (24.0)	18 (29.0)		43 (47.8)	40(44.9)	
1 (1 to 10)	29 (10.4)	24 (11.3)		9 (12.0)	6 (9.7)		167(18.9)	12 (13.5)	
2 (11 to 100)	40 (14.3)	47 (22.2)		14 (18.7)	14 (22.6)		10(11.1)	14 (15.7)	
3 (101 to 400)	61 (21.8)	39 (18.4)		16 (21.3)	14 (22.6)		11 (12.2)	10 (11.2)	
4 (>400)	87 (31.1)	57 (26.9)		18 (24.0)	10 (16.1)		9 (10.0)	13(14.6)	
Total coronary diameter stenosis									0.553
none (0%)	69 (24.6)	51 (24.1)	0.247	19 (25.3)	12 (19.4)	0.825	19 (21.1)	12 (13.5)	
Slight (1% to 24%)	28 (10.0)	11 (5.2)		6 (8.0)	8 (12.9)		9 (10.0)	14 (15.7)	
Mild (25% to 49%)	40 (14.3)	41 (19.3)		17 (22.7)	16 (25.8)		27 (30.0)	25 (28.1)	
Moderate (50% to 69%)	68 (24.3)	52 (24.5)		18 (24.0)	14 (22.6)		21 (23.3)	21 (23.6)	
Severe (70% to 99%)	75 (26.8)	57 (26.9)		15 (20.0)	12 (19.4)		14 (15.68)	17 (19.1)	
CAD-RADS classification									
0	68 (24.3)	52 (24.5)	0.392	19 (25.3)	12 (19.4)	0.738	19 (21.1)	15 (16.9)	0.734
1	29 (10.4)	13 (6.1)		5 (6.7)	8 (12.9)		9 (10.0)	13 (14.6)	
2	40 (14.3)	40 (18.9)		19 (25.3)	15 (24.2)		27 (30.0)	23 (25.8)	
3	67 (23.9)	51 (24.1)		17 (22.7)	15 (24.2)		20 (22.2)	19 (21.3)	
4	76 (27.1)	56 (26.4)		15 (20.0)	12 (19.4)		15 (16.7)	19 (21.3)	
5	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
LVEF (%)	55.8±6.3	54.9±5.9	0.108	53.2±6.7	52.7±5.9	0.647	52.5±6.2	52.1±7.0	0.686
LVEDV (mL)	121.6±11.8	120.7±13.1	0.425	116.6±11.6	114.7±13.0	0.368	108.6±12.4	108.3±12.1	0.870
LVESV (mL)	52.9±10.1	54.6±11.1	0.077	51.7±8.4	52.7±8.8	0.498	50.5±6.9	51.3±8.4	0.487
LVSV (mL)	68.7±10.0	67.5±14.5	0.278	64.7±10.0	62.0±14.5	0.201	58.2±14.5	57.1±12.1	0.583
LVMM (g)	102.8±19.9	103.5±12.9	0.656	100.4±15.1	98.4±13.4	0.418	86.9±12.7	85.4±10.2	0.385
FAI (HU)									
LAD	−78.0 (−81.0, −74.0)	−75.0 (−77.9, −72.0)	<0.001	−77.0 (−82.0, −73.0)	−75.0 (−77.3, −71.0)	0.002	−78.0 (−86.0, −72.0)	−81.0 (−89.0, −76.5)	0.013
LCX	−77.0 (−80.0, −74.0)	−75.0 (−78.3, −70.0)	<0.001	−78.3 (−83.0, −72.9)	−74.0 (−78.3, −69.0)	0.02	−76.0 (−81.0, −70.8)	−80.0 (−84.0, −75.0)	<0.001
RCA	−77.0 (−80.0, −74.0)	−75.0 (−78.0, −71.0)	<0.001	−78.0 (−81.0, −72.0)	−73.0 (−77.0, −71.0)	0.002	−78.0 (−83.3, −73.0)	−82.0 (−87.5, −77.0)	0.02

Values are mean ± standard deviation, median (interquartile range) or n (%). P values reflect the differences between before and after chemotherapy. CCTA, coronary computed tomography angiography; CAD-RADS, coronary artery disease-reporting and data system; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVMM, left ventricular myocardial mass; FAI, fat attenuation index; HU, Hounsfield unit; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.

https://dx.doi.org/10.21037/qims-24-944

Table S6 The comparison of CCTA parameters before and after chemoradiotherapy in thoracic cancer

Parameters	Lung cancer			Esophageal cancer			Breast cancer		
	Pre (n=223)	Post (n=140)	P	Pre (n=137)	Post (n=102)	P	Pre (n=68)	Post (n=65)	P
Total coronary artery calcium score			0.226			0.523			0.862
0 (0)	69 (30.9)	34 (24.3)		56 (40.9)	44 (43.1)		33 (48.5)	30(46.2)	
1 (1 to 10)	21 (9.4)	7 (5.0)		13 (9.5)	5 (4.9)		10 (14.7)	8 (12.35)	
2 (11 to 100)	39 (17.5)	30 (21.4)		21 (15.3)	12 (11.8)		13(19.1)	13 (20.0)	
3 (101 to 400)	40 (17.9)	33 (23.6)		22 (16.1)	22 (21.6)		11 (16.2)	11 (16.9)	
4 (>400)	54 (24.2)	36 (25.7)		25 (18.2)	19 (18.6)		1 (1.5)	3(4.6)	
Total coronary diameter stenosis									0.431
none (0%)	51 (22.9)	38 (27.1)	0.803	34 (24.8)	33 (32.4)	0.252	18 (26.5)	11 (16.9)	
Slight (1% to 24%)	19 (8.5)	9 (6.4)		10 (7.3)	7 (6.9)		4 (5.9)	3 (4.6)	
Mild (25% to 49%)	41 (18.4)	26 (18.6)		26 (19.0)	13 (12.7)		11 (16.2)	13 (20.0)	
Moderate (50% to 69%)	58 (26.0)	38 (27.1)		20 (14.6)	22 (21.6)		22 (32.4)	18 (27.7)	
Severe (70% to 99%)	54 (24.2)	29 (20.7)		47 (34.3)	27 (26.5)		13 (19.1)	20 (30.8)	
CAD-RADS classification									0.653
0	51 (22.9)	38 (27.1)	0.778	37 (27.0)	33 (32.4)	0.533	18 (26.5)	13 (20.0)	
1	19 (8.5)	9 (6.4)		7 (5.1)	7 (6.9)		4 (5.9)	3 (4.6)	
2	41 (18.4)	27 (19.3)		26 (19.0)	13 (12.7)		11 (16.2)	12 (18.5)	
3	57 (25.6)	37 (26.4)		23 (16.8)	21 (20.6)		22 (32.4)	18 (27.7)	
4	55 (24.7)	29 (20.7)		44 (32.1)	28 (27.5)		13 (19.1)	19 (29.2)	
5	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
LVEF (%)	55.3±6.7	54.3±7.3	0.182	55.0±8.1	54.5±9.0	0.653	52.5±5.2	52.1±6.0	0.681
LVEDV (mL)	119.6±14.4	118.7±15.3	0.572	121.6±10.9	119.1±12.6	0.102	108.6±11.4	108.3±12.1	0.883
LVESV (mL)	52.3±9.1	52.6±9.0	0.759	52.8±10.7	53.0±10.5	0.886	50.5±6.9	51.3±10.4	0.601
LVSV (mL)	67.4±11.7	66.2±13.4	0.369	68.7±13.5	66.1±11.4	0.117	58.2±12.5	57.1±14.1	0.634
LVMM (g)	95.3±15.2	97.8±14.2	0.119	97.9±10.5	98.6±14.4	0.664	86.9±12.7	85.4±10.2	0.455
FAI (HU)									
LAD	−78.0 (−81.0, −73.0)	−71.0 (−74.8, −67.0)	<0.001	−77.0 (−80.0, −73.0)	−73.0 (−76.0, −65.8)	0.039	−80.5 (−85.0, −74.3)	−87.0 (−93.0, −78.0)	0.01
LCX	−78.0 (−82.0, −72.0)	−72.0 (−74.0, −69.0)	<0.001	−78.0 (−80.0, −75.0)	−70.0 (−74.0, −67.0)	<0.001	−77.5 (−83.8, −71.0)	−83.0 (−90.0, −76.5)	0.011
RCA	−77.0 (−80.0, −74.0)	−71.5 (−75.0, −67.0)	<0.001	−76.0 (−80.0, −72.0)	−71.0 (−75.0, −67.8)	0.002	−79.0 (−84.0, −73.3)	−85.0 (−88.5, −79.5)	0.004

Values are mean ± standard deviation, median (interquartile range) or n (%). P values reflect the differences between before and after chemoradiotherapy. CCTA, coronary computed tomography angiography; CAD-RADS, coronary artery disease-reporting and data system; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVMM, left ventricular myocardial mass; FAI, fat attenuation index; HU, Hounsfield unit; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.

https://dx.doi.org/10.21037/qims-24-944

Table S7 Comparison of CCTA parameters between chemotherapy group and chemoradiotherapy group before and after treatment

Parameters	Pretreatment			Posttreatment		
	Chemotherapy (n=445)	Chemoradiotherapy (n=428)	P*	Chemotherapy (n=363)	Chemoradiotherapy (n=307)	P**
Total coronary artery calcium score			0.10			0.410
0 (0)	124 (27.9)	158 (36.9)		103 (28.4)	108 (35.2)	
1 (1 to 10)	55 (12.4)	43 (10.0)		42 (11.6)	20 (6.5)	
2 (11 to 100)	64 (14.3)	74 (17.3)		75 (20.7)	55 (17.9)	
3 (101 to 400)	88 (19.8)	73 (17.1)		63 (17.3)	66 (21.5)	
4 (>400)	114 (25.6)	80 (18.7)		80 (22.0)	58 (18.9)	
Total coronary diameter stenosis			0.740			0.122
none (0%)	107 (24.0)	103 (24.1)		75 (20.7)	82 (26.7)	
Slight (1% to 24%)	43 (9.7)	33 (7.7)		33 (9.0)	19 (6.2)	
Mild (25% to 49%)	84 (18.9)	78 (18.2)		82 (22.6)	52 (16.9)	
Moderate (50% to 69%)	107 (24.0)	100 (23.4)		87 (24.0)	78 (25.4)	
Severe (70% to 99%)	104 (23.4)	114 (26.6)		86 (23.7)	76 (24.8)	
CAD-RADS classification						
0	106 (23.8)	106 (24.8)	0.634	79 (21.8)	84 (27.4)	0.184
1	43 (9.7)	30 (7.0)		34 (9.4)	19 (6.2)	
2	86 (19.3)	78 (18.2)		78 (21.5)	52 (16.8)	
3	104 (23.4)	102 (23.8)		85 (23.3)	76 (24.8)	
4	106 (23.8)	112 (26.2)		87 (24.0)	76 (24.8)	
5	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
LVEF (%)	54.6±6.7	55.0±5.7	0.343	53.2±6.7	54.2±7.2	0.063
LVEDV (mL)	118.1±12.8	119.0±14.8	0.336	117.1±15.3	118.4±15.4	0.275
LVESV (mL)	52.6±8.8	52.5±8.4	0.864	53.3±8.3	52.9±8.2	0.532
LVSV (mL)	65.8±12.3	67.4±15.1	0.086	63.7±14.9	65.5±14.4	0.114
LVMM (g)	99.2±15.9	97.3±14.4	0.065	98.2±15.2	95.9±15.7	0.055
FAI (HU)						
LAD	−76.7±6.03	−76.6±6.31	0.845	−73.2±6.74	−70.3±6.47	<0.001
LCX	−76.4±6.47	−76.7±7.25	0.384	−73.2±8.10	−70.3±4.66	<0.001
RCA	−76.5±5.98	−76.3±6.52	0.709	−73.4±7.41	−70.6±6.19	<0.001

Values are mean ± standard deviation, median (interquartile range) or n (%). *, P values reflect the differences between chemotherapy group and chemoradiotherapy group in pretreatment; **, P values reflect the differences between chemotherapy group and chemoradiotherapy group in posttreatment. CCTA, coronary computed tomography angiography; CAD-RADS, coronary artery disease-reporting and data system; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVMM, left ventricular myocardial mass; FAI, fat attenuation index; HU, Hounsfield unit; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.

https://dx.doi.org/10.21037/qims-24-944

Table S8 The comparison of CCTA parameters between chemotherapy group and chemoradiotherapy group before and after treatment in lung cancer

Parameters	Pretreatment			Posttreatment		
	Chemotherapy (n=280)	Chemoradiotherapy (n=223)	P*	Chemotherapy (n=212)	Chemoradiotherapy (n=140)	P**
Total coronary artery calcium score			0.121			0.254
0 (0)	63 (22.5)	69 (30.9)		40 (44.9)	30 (46.2)	
1 (1 to 10)	29 (10.4)	21 (9.4)		12 (13.5)	8 (12.35)	
2 (11 to 100)	40 (14.3)	39 (17.5)		14 (15.7)	13 (20.0)	
3 (101 to 400)	61 (21.8)	40 (17.9)		10 (11.2)	11 (16.9)	
4 (>400)	87 (31.1)	54 (24.2)		13 (14.6)	3 (4.6)	
Total coronary diameter stenosis			0.696			0.715
none (0%)	69 (24.6)	51 (22.9)		12 (13.5)	11 (16.9)	
Slight (1% to 24%)	28 (10.0)	19 (8.5)		14 (15.7)	3 (4.6)	
Mild (25% to 49%)	40 (14.3)	41 (18.4)		25 (28.1)	13 (20.0)	
Moderate (50% to 69%)	68 (24.3)	58 (26.0)		21 (23.6)	18 (27.7)	
Severe (70% to 99%)	75 (26.8)	54 (24.2)		17 (19.1)	20 (30.8)	
CAD-RADS classification						
0	68 (24.3)	51 (22.9)	0.687	15 (16.9)	13 (20.0)	0.814
1	29 (10.4)	19 (8.5)		13 (14.6)	3 (4.6)	
2	40 (14.3)	41 (18.4)		23 (25.8)	12 (18.5)	
3	67 (23.9)	57 (25.6)		19 (21.3)	18 (27.7)	
4	76 (27.1)	55 (24.7)		19 (21.3)	19 (29.2)	
5	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
LVEF (%)	55.8±6.2	55.3±5.8	0.356	53.7±8.2	54.3±8.3	0.504
LVEDV (mL)	121.6±12.8	119.6±14.4	0.100	120.2±13.1	118.7±10.3	0.254
LVESV (mL)	52.8±9.0	52.2±9.1	0.460	54.7±10.0	52.6±10.0	0.055
LVSV (mL)	68.7±10.0	67.4±11.7	0.180	67.5±14.5	66.2±13.4	0.397
LVMM (g)	100.4±19.9	99.3±15.2	0.496	101.4±12.8	99.6±17.9	0.272
FAI (HU)						
LAD	−78.0 (−81.0, −74.0)	−78.0 (−81.0, −73.0)	0.639	−81.0 (−89.0, −76.5)	−87.0 (−93.0, −78.0)	<0.001
LCX	−77.0 (−80.0, −74.0)	−78.0 (−82.0, −72.0)	0.448	−80.0 (−84.0, −75.0)	−83.0 (−90.0, −76.5)	<0.001
RCA	−77.0 (−80.0, −74.0)	−77.0 (−80.0, −74.0)	0.823	−82.0 (−87.5, −77.0)	−85.0 (−88.5, −79.5)	<0.001

Values are mean ± standard deviation, median (interquartile range) or n (%). *, P values reflect the differences between chemotherapy group and chemoradiotherapy group in pretreatment; **, P values reflect the differences between chemotherapy group and chemoradiotherapy group in posttreatment. CCTA, coronary computed tomography angiography; CAD-RADS, coronary artery disease-reporting and data system; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVMM, left ventricular myocardial mass; FAI, fat attenuation index; HU, Hounsfield unit; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.

https://dx.doi.org/10.21037/qims-24-944

Table S9 The comparison of CCTA parameters between chemotherapy group and chemoradiotherapy group before and after treatment in esophageal cancer

Parameters	Pretreatment (n=212)			Posttreatment (n=164)		
	Chemotherapy (n=75)	Chemoradiotherapy (n=137)	P*	Chemotherapy (n=62)	Chemoradiotherapy (n=102)	P**
Total coronary artery calcium score			0.19			0.175
0 (0)	18 (24.0)	56 (40.9)		18 (29.0)	44 (43.1)	
1 (1 to 10)	9 (12.0)	13 (9.5)		6 (9.7)	5 (4.9)	
2 (11 to 100)	14 (18.7)	21 (15.3)		14 (22.6)	12 (11.8)	
3 (101 to 400)	16 (21.3)	22 (16.1)		14 (22.6)	22 (21.6)	
4 (>400)	18 (24.0)	25 (18.2)		10 (16.1)	19 (18.6)	
Total coronary diameter stenosis			0.189			0.076
none (0%)	19 (25.3)	34 (24.8)		12 (19.4)	33 (32.4)	
Slight (1% to 24%)	6 (8.0)	10 (7.3)		8 (12.9)	7 (6.9)	
Mild (25% to 49%)	17 (22.7)	26 (19.0)		16 (25.8)	13 (12.7)	
Moderate (50% to 69%)	18 (24.0)	20 (14.6)		14 (22.6)	22 (21.6)	
Severe (70% to 99%)	15 (20.0)	47 (34.3)		12 (19.4)	27 (26.5)	
CAD-RADS classification						0.087
0	19 (25.3)	37 (27.0)	0.328	12 (19.4)	33 (32.4)	
1	5 (6.7)	7 (5.1)		8 (12.9)	7 (6.9)	
2	19 (25.3)	26 (19.0)		15 (24.2)	13 (12.7)	
3	17 (22.7)	23 (16.8)		15 (24.2)	21 (20.6)	
4	15 (20.0)	44 (32.1)		12 (19.4)	28 (27.5)	
5	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
LVEF (%)	52.7±6.9	54.0±6.1	0.158	52.3±10.7	54.5±11.0	0.211
LVEDV (mL)	116.6±11.6	119.6±10.9	0.062	111.7±13.0	115.7±13.6	0.065
LVESV (mL)	54.4±9.3	52.8±9.7	0.245	55.7±10.4	53.6±10.5	0.214
LVSV (mL)	62.7±11.7	63.7±13.4	0.588	60.1±12.4	62.1±11.4	0.294
LVMM (g)	100.4±15.2	97.9±12.5	0.199	98.4±13.3	98.6±14.4	0.929
FAI (HU)						
LAD	−77.0 (−82.0, −73.0)	−77.0 (−80.0, −73.0)	0.299	−75.0 (−77.3, −71.0)	−73.0 (−76.0, −65.8)	<0.001
LCX	−78.3 (−83.0, −72.9)	−78.0 (−80.0, −75.0)	0.631	−74.0 (−78.3, −69.0)	−70.0 (−74.0, −67.0)	<0.001
RCA	−78.0 (−81.0, −72.0)	−76.0 (−80.0, −72.0)	0.349	−73.0 (−77.0, −71.0)	−71.0 (−75.0, −67.8)	<0.001

Values are mean ± standard deviation, median (interquartile range) or n (%). *, P values reflect the differences between chemotherapy group and chemoradiotherapy group in pretreatment; **, P values reflect the differences between chemotherapy group and chemoradiotherapy group in posttreatment. CCTA, coronary computed tomography angiography; CAD-RADS, coronary artery disease-reporting and data system; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVMM, left ventricular myocardial mass; FAI, fat attenuation index; HU, Hounsfield unit; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.

https://dx.doi.org/10.21037/qims-24-944

Table S10 The comparison of CCTA parameters between chemotherapy group and chemoradiotherapy group before and after treatment in breast cancer

Parameters	Pretreatment (n=158)			Posttreatment (n=154)		
	Chemotherapy (n=90)	Chemoradiotherapy (n=68)	P*	Chemotherapy (n=89)	Chemoradiotherapy (n=65)	P**
Total coronary artery calcium score			0.136			0.293
0 (0)	43 (47.8)	33 (48.5)		40 (44.9)	30 (46.2)	
1 (1 to 10)	167 (18.9)	10 (14.7)		12 (13.5)	8 (12.35)	
2 (11 to 100)	10 (11.1)	13 (19.1)		14 (15.7)	13 (20.0)	
3 (101 to 400)	11 (12.2)	11 (16.2)		10 (11.2)	11 (16.9)	
4 (>400)	9 (10.0)	1 (1.5)		13 (14.6)	3 (4.6)	
Total coronary diameter stenosis			0.215			0.096
none (0%)	19 (21.1)	18 (26.5)		12 (13.5)	11 (16.9)	
Slight (1% to 24%)	9 (10.0)	4 (5.9)		14 (15.7)	3 (4.6)	
Mild (25% to 49%)	27 (30.0)	11 (16.2)		25 (28.1)	13 (20.0)	
Moderate (50% to 69%)	21 (23.3)	22 (32.4)		21 (23.6)	18 (27.7)	
Severe (70% to 99%)	14 (15.68)	13 (19.1)		17 (19.1)	20 (30.8)	
CAD-RADS classification						
0	19 (21.1)	18 (26.5)	0.201	15 (16.9)	13 (20.0)	0.179
1	9 (10.0)	4 (5.9)		13 (14.6)	3 (4.6)	
2	27 (30.0)	11 (16.2)		23 (25.8)	12 (18.5)	
3	20 (22.2)	22 (32.4)		19 (21.3)	18 (27.7)	
4	15 (16.7)	13 (19.1)		19 (21.3)	19 (29.2)	
5	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
LVEF (%)	52.5±6.3	53.9±6.1	0.163	52.1±11.0	53.4±10.5	0.461
LVEDV (mL)	108.6±14.4	107.6±15.0	0.672	108.3±12.0	107.7±13.5	0.772
LVESV (mL)	52.4±6.9	53.1±7.8	0.552	51.2±10.4	53.6±10.3	0.158
LVSV (mL)	56.2±10.8	54.5±12.4	0.360	55.0±12.0	53.1±13.2	0.354
LVMM (g)	86.9±12.7	89.7±14.4	0.197	85.4±10.2	87.4±11.0	0.247
FAI (HU)						
LAD	−78.0 (−86.0, −72.0)	−80.5 (−85.0, −74.3)	0.207	−81.0 (−89.0, −76.5)	−87.0 (−93.0, −78.0)	<0.001
LCX	−76.0 (−81.0, −70.8)	−77.5 (−83.8, −71.0)	0.324	−80.0 (−84.0, −75.0)	−83.0 (−90.0, −76.5)	<0.001
RCA	−78.0 (−83.3, −73.0)	−79.0 (−84.0, −73.3)	0.477	−82.0 (−87.5, −77.0)	−85.0 (−88.5, −79.5)	<0.001

Values are mean ± standard deviation, median (interquartile range) or n (%). *, P values reflect the differences between chemotherapy group and chemoradiotherapy group in pretreatment; **, P values reflect the differences between chemotherapy group and chemoradiotherapy group in posttreatment. CCTA, coronary computed tomography angiography; CAD-RADS, coronary artery disease-reporting and data system; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVMM, left ventricular myocardial mass; FAI, fat attenuation index; HU, Hounsfield unit; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.

https://dx.doi.org/10.21037/qims-24-944



Figure S1 Kaplan-Meier survival curves of MACE stratified by FAI_LAD for lung cancer patients before chemotherapy and chemoradiotherapy. (A) The MACEs-free survival rates in patients with high FAI_LAD group (≥−70.1 HU) were lower than those low FAI_LAD group (<−70.1 HU) before chemotherapy. (B) The MACEs-free survival rates in patients with high FAI_LAD group (≥−70.1 HU) were lower than those low FAI_LAD group (<−70.1 HU) before chemoradiotherapy. MACE, main adverse cardiovascular events; FAI_LAD, fat attenuation index of left anterior descending artery; HU, Hounsfield unit.



Figure S2 Kaplan-Meier survival curves of MACE stratified by FAI_LCX for lung cancer patients before chemotherapy and chemoradiotherapy. (A) The MACEs-free survival rates in patients with high FAI_LCX group (≥−70.1 HU) were lower than those low FAI_LCX group (<−70.1 HU) before chemotherapy. (B) The MACEs-free survival rates in patients with high FAI_LCX group (≥−70.1 HU) were lower than those low FAI_LCX group (<−70.1 HU) before chemoradiotherapy. MACE, main adverse cardiovascular events; FAI_LCX, fat attenuation index of left circumflex artery; HU, Hounsfield unit.



Figure S3 Kaplan-Meier survival curves of MACE stratified by FAI_RCA for lung cancer patients before chemotherapy and chemoradiotherapy. (A) The MACEs-free survival rates in patients with high FAI_RCA group (≥−70.1 HU) were lower than those low FAI_RCA group (<−70.1 HU) before chemotherapy. (B) The MACEs-free survival rates in patients with high FAI_RCA group (≥−70.1 HU) were lower than those low FAI_RCA group (<−70.1 HU) before chemoradiotherapy. MACE, main adverse cardiovascular events; FAI_RCA, fat attenuation index of right coronary artery; HU, Hounsfield unit.

https://dx.doi.org/10.21037/qims-24-944



Figure S4 Kaplan-Meier survival curves of MACE stratified by FAI_LAD for esophageal cancer patients before chemotherapy and chemoradiotherapy. (A) The MACEs-free survival rates in patients with high FAI_LAD group (≥−70.1 HU) were lower than those low FAI_LAD group (<−70.1 HU) before chemotherapy. (B) The MACEs-free survival rates in patients with high FAI_LAD group (≥−70.1 HU) were lower than those low FAI_LAD group (<−70.1 HU) before chemoradiotherapy. MACE, main adverse cardiovascular events; FAI_LAD, fat attenuation index of left anterior descending artery; HU, Hounsfield unit.



Figure S5 Kaplan-Meier survival curves of MACE stratified by FAI_LCX for esophageal cancer patients before chemotherapy and chemoradiotherapy. (A) The MACEs-free survival rates in patients with high FAI_LCX group (≥−70.1 HU) were lower than those low FAI_LCX group (<−70.1 HU) before chemotherapy. (B) The MACEs-free survival rates in patients with high FAI_LCX group (≥−70.1 HU) were lower than those low FAI_LCX group (<−70.1 HU) before chemoradiotherapy. MACE, main adverse cardiovascular events; FAI_LCX, fat attenuation index of left circumflex artery; HU, Hounsfield unit.



Figure S6 Kaplan-Meier survival curves of MACE stratified by FAI_RCA for esophageal cancer patients before chemotherapy and chemoradiotherapy. (A) The MACEs-free survival rates in patients with high FAI_RCA group (≥−70.1 HU) were lower than those low FAI_RCA group (<−70.1 HU) before chemotherapy. (B) The MACEs-free survival rates in patients with high FAI_RCA group (≥−70.1 HU) were lower than those low FAI_RCA group (<−70.1 HU) before chemoradiotherapy. MACE, main adverse cardiovascular events; FAI_RCA, fat attenuation index of right coronary artery; HU, Hounsfield unit.

https://dx.doi.org/10.21037/qims-24-944



Figure S7 Kaplan-Meier survival curves of MACE stratified by FAI_LAD for breast cancer patients before chemotherapy and chemoradiotherapy. (A) The MACEs-free survival rates in patients with high FAI_LAD group (≥−70.1 HU) were lower than those low FAI_LAD group (<−70.1 HU) before chemotherapy. (B) The MACEs-free survival rates in patients with high FAI_LAD group (≥−70.1 HU) were lower than those low FAI_LAD group (<−70.1 HU) before chemoradiotherapy. MACE, main adverse cardiovascular events; FAI_LAD, fat attenuation index of left anterior descending artery; HU, Hounsfield unit.



Figure S8 Kaplan-Meier survival curves of MACE stratified by FAI_LCX for breast cancer patients before chemotherapy and chemoradiotherapy. (A) The MACEs-free survival rates in patients with high FAI_LCX group (≥−70.1 HU) were lower than those low FAI_LCX group (<−70.1 HU) before chemotherapy. (B) The MACEs-free survival rates in patients with high FAI_LCX group (≥−70.1 HU) were lower than those low FAI_LCX group (<−70.1 HU) before chemoradiotherapy. MACE, main adverse cardiovascular events; FAI_LCX, fat attenuation index of left circumflex artery; HU, Hounsfield unit.



Figure S9 Kaplan-Meier survival curves of MACE stratified by FAI_RCA for breast cancer patients before chemotherapy and chemoradiotherapy. (A) The MACEs-free survival rates in patients with high FAI_RCA group (≥−70.1 HU) were lower than those low FAI_RCA group (<−70.1 HU) before chemotherapy. (B) The MACEs-free survival rates in patients with high FAI_RCA group (≥−70.1 HU) were lower than those low FAI_RCA group (<−70.1 HU) before chemoradiotherapy. MACE, main adverse cardiovascular events; FAI_RCA, fat attenuation index of right coronary artery; HU, Hounsfield unit.

https://dx.doi.org/10.21037/qims-24-944